454 LONG-TERM ADMINISTRATION OF THE SECRETIN RECEPTOR ANTAGONIST, SCT 5-27, INHIBITS BILIARY SENESCENCE AND LIVER FIBROSIS OF PRIMARY SCLEROSING CHOLANGITIS (PSC) IN THE MDR2-/- MOUSE MODEL.